Pharmacokinetics and hepatic uptake of gliquidone affected by Huangqi injection
Tóm tắt
The root of Astragalus membranaceus also known as Huang Qi in China is a common traditional Chinese herb with extensive pharmacological activities. Huangqi injection (HI), a common preparation of Huang Qi, was wildly co-administered with gliquidone to treat diabetes mellitus and diabetic nephropathy in clinic of China. The aim of the study was to investigate the effect of HI on the pharmacokinetics and hepatic uptake of gliquidone and related mechanism to ensure the safety and efficacy of their usage. Normal rats (n = 5) and streptozotocin (STZ)-induced diabetic rats (n = 5) were administered orally with 120 mg/kg gliquidone alone or in combination with 8 ml/kg HI (i.v.), HI was given intravenously 5 min before that of gliquidone. The plasma concentration of gliquidone was determined by HPLC-fluorescence. In addition, hepatic uptake of gliquidone with or without HI was evaluated in fresh primary rat hepatocytes. Co-administration of HI with gliquidone could significantly increased the bioavailability of gliquidone in normal and STZ-induced diabetic rats (n = 5); the concentration of gliquidone in fresh primary rat hepatocytes was greatly decreased by HI. This study suggested that when HI and gliquidone co-administering to normal and diabetic rats, the pharmacokinetics of gliquidone was greatly changed, and these changes connect with HI inhibiting hepatic uptake of gliquidone, and transportation of gliquidone across liver mucosal membrane inhibited by HI would be the main mechanisms.
Tài liệu tham khảo
Bi ZJ (2008) Application of Astragalus injection on 68 patients with diabetic nephropathy. Chin J Integr Med Cardio–Cerebro Vasc Dis 6:114–115
Chen QJ, Yang L, Wang H (2005) The effect of Astragalus on human renal inter-stitial fibroblasts proliferation and TGF- β1 expression. J Zhenzhou Univ 9:871–873
Chen W, Li YM, Yu MH (2008) Astragalus polysaccharides: an effective treatment for diabetes prevention in NOD mice. Exp Clin Endocrinol Diabetes 116:468–474
Chen X, Peng L-H, Li N, Li Q-M, Li P, Fung K-P, Leung P-C, Gao J-Q (2012) The healing and anti-scar effects of astragaloside IV on the wound repair in vitro and in vivo. J Ethnopharmacol 139:721–727
Cheng ZR, Fang BQ, Cheng ZF, Song JZ (2002) Observation of treatment of early stage of diabetic nephropathy with Astragalus injection. Liaoning J Pract Diabetes 10:34–35
Chinese Pharmacopoeia Commission (2002) Huangqi Zhusheye. Drug Standard of China 3: 33–4
Cho WCS, Leung KN (2007a) In vitro and in vivo immunomodulating and immunorestorative effects of Astragalus membranaceus. J Ethnopharmacol 113:132–141
Cho WCS, Leung KN (2007b) In vitro and in vivo anti-tumor effects of Astragalus membranaceus. Cancer Lett 252:43–54
Gelbrich T, Haddow MF, Griesser UJ (2011) Gliquidone. Acta Crystallogr Sect E Struct Rep Online 67:o1343
Hartmann B, Czock D, Keller F (2010) Drug therapy in patients with chronic renal failure. Dtsch Arztebl Int 107:647–655 quiz 55-6
Holstein A, Hahn M, Patzer O, Seeringer A, Kovacs P, Stingl J (2011) Impact of clinical factors and CYP2C9 variants for the risk of severe sulfonylurea-induced hypoglycemia. Eur J Clin Pharmacol 67:471–476
Hong SS, Seo K, Lim S-C, Han H-K (2007) Interaction characteristics of flavonoids with human organic anion transporter 1 (hOAT1) and 3 (hOAT3). Pharmacol Res 56:468–473
Huang CL, Lu YP (2003) Effect of Astragalus injection on insulin resistance in auxiliary treating patients with diabetes mellitus type 2. Zhongguo Zhong Xi Yi Jie He Za Zhi 23:779–780
Hui D, Tie-jun F, Fan Z, Zhong-rong L, Li-sheng D (2002) Chemical constituents of Huangqi injection. Nat Prod Res Dev 14:14–17
Li M, Wang W, Xue J, Gu Y, Lin S (2011) Meta-analysis of the clinical value of Astragalus membranaceus in diabetic nephropathy. J Ethnopharmacol 133:412–419
Li Y, Wei Y, Zhang F, Wang D, Wu X (2012) Changes in the pharmacokinetics of glibenclamide in rats with streptozotocin-induced diabetes mellitus. Acta Pharm Sinica B 2:198–204
Lins L, Brasseur R, Malaisse WJ (1996) Pharmacology of the hypoglycaemic sulphonylurea gliquidone III. Conformational analysis. Pharmacol Res 34:9–10
Malaisse WJ (2006) Gliquidone contributes to improvement of type 2 diabetes mellitus management: a review of pharmacokinetic and clinical trial data. Drugs R D 7:331–337
Marles RJ, Farnsworth NR (1995) Antidiabetic plants and their active constituents. Phytomedicine 2:137–189
Morris ME, Zhang S (2006) Flavonoid—drug interactions: effects of flavonoids on ABC transporters. Life Sci 78:2116–2130
Obach RS (2000) Inhibition of human cytochrome P450 enzymes by constituents of St. John’s Wort, an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther 294:88–95
Qu LL, Su YL, Li CX, Hou GH (2010) Astragalus membranaceus injection delayed allograft survival related with CD4 + CD25 + regulatory T cells. Transpl Proc 42:3793–3797
Rybka J, Gregorova A, Zmydlena A (1988) Clinical experience with Glurenorm in type 2 diabetics with renal insufficiency. Vnitr Lek 34:786–792
Scollon EJ, Starr JM, Godin SJ, DeVito MJ, Hughes MF (2009) In vitro metabolism of pyrethroid pesticides by rat and human hepatic microsomes and cytochrome p450 isoforms. Drug Metab Dispos 37:212–218
Seglen PO (1976) Preparation of isolated rat liver cells. Methods Cell Biol 13:29–83
Sun W-Y, Wei W, Wu L, Gui S-Y, Wang H (2007) Effects and mechanisms of extract from Paeonia lactiflora and Astragalus membranaceus on liver fibrosis induced by carbon tetrachloride in rats. J Ethnopharmacol 112:514–523
Tirona RG, Bailey DG (2006) Herbal product–drug interactions mediated by induction. Br J Clin Pharmacol 61:677–681
Tornio A, Niemi M, Neuvonen PJ, Backman JT (2012) Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications. Trends Pharmacol Sci 33:312–322
Wang H, Cheng JD, Montgomery D, Cheng KC (2009) Evaluation of the binding orientations of testosterone in the active site of homology models for CYP2C11 and CYP2C13. Biochem Pharmacol 78:406–413
Wang X, Lee WYW, Or PMY, Yeung JHK (2010) Pharmacokinetic interaction studies of tanshinones with tolbutamide, a model CYP2C11 probe substrate, using liver microsomes, primary hepatocytes and in vivo in the rat. Phytomedicine 17:203–211
Weber CC, Kressmann S, Fricker G, Muller WE (2004) Modulation of P-glycoprotein function by St. John’s wort extract and its major constituents. Pharmacopsychiatry 37:292–298
Zacharova A, Siller M, Spicakova A, Anzenbacherova E, Skottova N, Anzenbacher P, Vecera R (2012a) Rosuvastatin suppresses the liver microsomal CYP2C11 and CYP2C6 expression in male Wistar rats. Xenobiotica 42:713–716
Zacharova A, Siller M, Spicakova A, Anzenbacherova E, Skottova N, Anzenbacher P, Vecera R (2012b) Rosuvastatin suppresses the liver microsomal CYP2C11 and CYP2C6 expression in male Wistar rats. Xenobiotica 42:731–736
Zhang SJ, Liu CY (1997) Pharmacology and clinical uses of gliquidone. Chin J New Drugs 6:245–247
Zhang J, Xie X, Li C, Fu P (2009) Systematic review of the renal protective effect of Astragalus membranaceus (root) on diabetic nephropathy in animal models. J Ethnopharmacol 126:189–196
Zhou S, Chan E, Pan SQ, Huang M, Lee EJ (2004) Pharmacokinetic interactions of drugs with St. John’s wort. J Psychopharmacol 18:262–276